Albumin-bound paclitaxel

Drug Profile

Albumin-bound paclitaxel

Alternative Names: ABI-007; Abraxane; Coraxane; Coroxane; Nab-Paclitaxel; Systemic nanoparticle albumin-bound paclitaxel

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Abraxis BioScience
  • Developer Abraxis BioScience; Australian and New Zealand Urogenital and Prostate Cancer Group; Cambridge University Hospitals; Cancer Research UK; Celgene Corporation; Columbia University; Genentech; M. D. Anderson Cancer Center; Mayo Clinic; NCIC Clinical Trials Group; New York University School of Medicine; Oncosur; PrECOG; Southeastern Gynecologic Oncology; Taiho Pharmaceutical; University of Iowa; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Small cell lung cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Bladder cancer; Ovarian cancer; Prostate cancer
  • Discontinued Coronary artery restenosis; Peripheral arterial disorders; Vascular restenosis

Most Recent Events

  • 29 Mar 2017 University of Utah terminates a phase I trial for Breast cancer (Late-stage disease, Combination therapy, Neoadjuvant therapy) in USA (NCT01090128)
  • 13 Mar 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (IV) (NCT02733250)
  • 20 Dec 2016 Interim efficacy and adverse events data from a phase I trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top